1
|
Intermolecular hydrogen bonds in hetero-complexes of biologically active aromatic ligands: Monte Carlo simulations results. Struct Chem 2015. [DOI: 10.1007/s11224-015-0696-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
2
|
Sun Y, Sheng Z, Ma C, Tang K, Zhu R, Wu Z, Shen R, Feng J, Wu D, Huang D, Huang D, Fei J, Liu Q, Cao Z. Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nat Commun 2015; 6:8481. [PMID: 26412466 PMCID: PMC4598846 DOI: 10.1038/ncomms9481] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Accepted: 08/27/2015] [Indexed: 12/12/2022] Open
Abstract
The identification of synergistic chemotherapeutic agents from a large pool of candidates is highly challenging. Here, we present a Ranking-system of Anti-Cancer Synergy (RACS) that combines features of targeting networks and transcriptomic profiles, and validate it on three types of cancer. Using data on human β-cell lymphoma from the Dialogue for Reverse Engineering Assessments and Methods consortium we show a probability concordance of 0.78 compared with 0.61 obtained with the previous best algorithm. We confirm 63.6% of our breast cancer predictions through experiment and literature, including four strong synergistic pairs. Further in vivo screening in a zebrafish MCF7 xenograft model confirms one prediction with strong synergy and low toxicity. Validation using A549 lung cancer cells shows similar results. Thus, RACS can significantly improve drug synergy prediction and markedly reduce the experimental prescreening of existing drugs for repurposing to cancer treatment, although the molecular mechanism underlying particular interactions remains unknown. Predicting combinations of chemotherapeutic drugs that act synergistically is challenging. Here the authors take a computational approach to predict synergistic pairs, validate novel pairs using several cancer cell lines, and assess toxicity in a zebrafish xenograft model.
Collapse
Affiliation(s)
- Yi Sun
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Zhen Sheng
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Chao Ma
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Kailin Tang
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Ruixin Zhu
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Zhuanbin Wu
- Shanghai Research Center for Model Organisms, Shanghai 200092, China
| | - Ruling Shen
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.,Shanghai Research Center for Model Organisms, Shanghai 200092, China
| | - Jun Feng
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Dingfeng Wu
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Danyi Huang
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Dandan Huang
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Jian Fei
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Qi Liu
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| | - Zhiwei Cao
- School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
| |
Collapse
|
3
|
Abstract
Combination chemotherapy and nanoparticle drug delivery are two areas that have shown significant promise in cancer treatment. Combined therapy of two or more drugs promotes synergism among the different drugs against cancer cells and suppresses drug resistance through distinct mechanisms of action. Nanoparticle drug delivery, on the other hand, enhances therapeutic effectiveness and reduces side effects of the drug payloads by improving their pharmacokinetics. These two active research fields have been recently merged to further improve the efficacy of cancer therapeutics. This review article summarizes the recent efforts in developing nanoparticle platforms to concurrently deliver multiple types of drugs for combination chemotherapy. We also highlight the challenges and design specifications that need to be considered in optimizing nanoparticle-based combination chemotherapy.
Collapse
|
4
|
Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol 2011; 4:49. [PMID: 22128838 PMCID: PMC3287147 DOI: 10.1186/1756-8722-4-49] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Accepted: 12/01/2011] [Indexed: 11/10/2022] Open
Abstract
Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currently FDA approved for second-line treatment of mantle cell lymphoma (MCL). Bortezomib exerts its activity in part through the generation of reactive oxygen species (ROS) and also by the induction of apoptosis.We previously validated CD22 as a potential target in treating NHL and have shown that the anti-CD22 ligand blocking antibody, HB22.7, has significant independent lymphomacidal properties in NHL xenograft models. We sought to determine whether or not these agents would work synergistically to enhance cytotoxicity. Our results indicate that treatment of NHL cell lines with HB22.7 six hours prior to bortezomib significantly diminished cell viability. These effects were not seen when the agents were administered alone or when bortezomib was administered prior to HB22.7. Additionally, HB22.7 treatment prior to bortezomib increased apoptosis in part through enhanced ROS generation. Finally, in a mouse xenograft model, administration of HB22.7 followed 24 hours later by bortezomib resulted in 23% smaller tumor volumes and 20% enhanced survival compared to treatment with the reverse sequence. Despite the increased efficacy of HB22.7 treatment followed by bortezomib, there was no corresponding decrease in peripheral blood cell counts, indicating no increase in toxicity. Our results suggest that pre-treatment with HB22.7 increases bortezomib cytotoxicity, in part through increased reactive oxygen species and apoptosis, and that this sequential treatment combination has robust efficacy in vivo.
Collapse
Affiliation(s)
- Shiloh M Martin
- Department of Internal Medicine, Division of Hematology and Oncology, University of California-Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
| | | | | | | | | | | | | |
Collapse
|
5
|
DAVIES DAVIDB, VESELKOV DENNISA, KODINTSEV VENIAMINV, EVSTIGNEEV MAXIMP, VESELKOV ALEXEIN. 1H NMR investigation of the hetero-association of aromatic molecules in aqueous solution: factors involved in the stabilization of complexes of daunomycin and acridine drugs. Mol Phys 2009. [DOI: 10.1080/00268970009483399] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- DAVID B. DAVIES
- a School of Biological and Chemical Sciences, Birkbeck College, University of London , Gordon House, 29 Gordon Square, London , WC1H 0PP , UK
| | - DENNIS A. VESELKOV
- a School of Biological and Chemical Sciences, Birkbeck College, University of London , Gordon House, 29 Gordon Square, London , WC1H 0PP , UK
| | - VENIAMIN V. KODINTSEV
- b Department of Physics and Chemistry , Sevastopol State Technical University , Sevastopol , 99053 , Crimea , Ukraine
| | - MAXIM P. EVSTIGNEEV
- b Department of Physics and Chemistry , Sevastopol State Technical University , Sevastopol , 99053 , Crimea , Ukraine
| | - ALEXEI N. VESELKOV
- b Department of Physics and Chemistry , Sevastopol State Technical University , Sevastopol , 99053 , Crimea , Ukraine
| |
Collapse
|
6
|
Goldoni M, Caglieri A, Poli D, Vettori MV, Ceccatelli S, Mutti A. Methylmercury at low doses modulates the toxicity of PCB153 on PC12 neuronal cell line in asynchronous combination experiments. Food Chem Toxicol 2007; 46:808-11. [PMID: 17980472 DOI: 10.1016/j.fct.2007.09.104] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Revised: 06/18/2007] [Accepted: 09/14/2007] [Indexed: 10/22/2022]
Abstract
Me-Hg and PCB153 are known neurotoxic contaminants which tend to accumulate in food, particularly in fish. Aim of this study was to perform asynchronous and combined exposure to Me-Hg and PCB153 in a neuronal rat cell line (PC12) to better characterise the antagonism observed at some combination concentrations. PC12 cells were treated with three concentrations of Me-Hg (0.1-0.5-1.0 microM) and PCB153 at one concentration (175 microM) in single and combined asynchronous exposures, using viability (MTT assay) as end-point. At all concentrations used, a statistically significant antagonistic effect was observed when Me-Hg preceded PCB153 exposure, while effect was additive when PCB153 preceded Me-Hg exposure. The antagonism is particularly evident at low concentrations of Me-Hg (0.1 microM). In conclusion, combined asynchronous exposure showed that whereas Me-Hg can modulate PCB153 toxicity, the opposite seems not to be true. Therefore, the use of asynchronous exposure could be a promising approach to study the mechanisms of toxicity of binary mixtures.
Collapse
Affiliation(s)
- M Goldoni
- Laboratory of Industrial Toxicology, Department of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Via Gramsci 14, 43100 Parma, Italy.
| | | | | | | | | | | |
Collapse
|
7
|
Waterhouse DN, Bally MB. Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. Nanomedicine (Lond) 2007; 1:359-63. [PMID: 17716167 DOI: 10.2217/17435889.1.3.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Evaluation of: Sengupta S, Eavarone D, Capila I et al.: Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 468–469 (2005) [1] . Cancer treatment has mainly evolved in small increments over the years, with a few key exceptions, where innovations in the type of therapy or delivery have resulted in large steps forward in the reduction of patient morbidity. In the work presented by Sengupta and colleagues, one such exception is presented in the form of a combination drug carrier based on nanotechnology that enables precise temporal control over the release of agents with diverse and complimentary antitumor activity.
Collapse
Affiliation(s)
- Dawn N Waterhouse
- Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, BC, Canada.
| | | |
Collapse
|
8
|
Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol 2007; 59:749-57. [PMID: 17333195 PMCID: PMC3665286 DOI: 10.1007/s00280-006-0329-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2006] [Accepted: 08/14/2006] [Indexed: 11/25/2022]
Abstract
PURPOSE This study evaluated the cytotoxic effects of imexon (NSC-714597) in tumor cells when combined with a broad panel of chemotherapeutic drugs. METHODS The sulforhodamine B (SRB) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assays were used to analyze the degree of growth inhibition for the combination studies in the A375 human malignant melanoma and RPMI 8226 human multiple myeloma cell lines, respectively. Cells were continuously exposed to both drugs at a constant molar ratio for 4-5 days. Combination effects were analyzed using the Median Effect method. Statistical significance was inferred if the 95% confidence interval for the combination interaction (C.I.) values for a particular two-drug combination did not include 1.0 (additivity). Synergy was inferred for C.I. values<1.0 and antagonism for CI values>1.0. RESULTS Imexon was synergistic when combined with DNA-binding agents (cisplatin, dacarbazine, melphalan) and pyrimidine-based antimetabolites (cytarabine, fluorouracil, gemcitabine) in both cell lines. Antagonistic combinations with imexon included methotrexate and the topoisomerase I (TOPO I) and II (TOPO II) inhibitors irinotecan, doxorubicin, mitoxantrone and etoposide. Docetaxel was synergistic with imexon in both cell lines whereas paclitaxel and fludarabine showed a mixed result. Dexamethasone and the proteasome inhibitor bortezomib showed synergy in myeloma cells and additivity in the melanoma cells. The vinca alkaloid, vinorelbine, and the multi-targeted antifol, pemetrexed, were additive with imexon in both cell lines. DISCUSSION The consistent synergy seen for imexon and alkylating agents may relate to the sulfhydryl-lowering effect of imexon, which would render cells more sensitive to electrophilic species from the alkylators. The marked synergy noted with pyrimidine-based antimetabolites was unexpected and may relate to the induction of cell cycle arrest in S-phase. The strong antagonism noted for imexon with topoisomerase I and II inhibitors may be due to the effect of imexon at increasing oxidant levels which are known to antagonize the cytotoxic effects of topoisomerase poisons. In contrast, the synergy seen with bortezomib in myeloma cells may be related to an increase in reactive oxygen species (ROS) from both drugs. These results suggest that combinations of imexon with alkylating agents and pyrimidine-based antimetabolites are rational to pursue in therapeutic studies in vivo.
Collapse
Affiliation(s)
- Julie Scott
- College of Medicine, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85724, USA
- Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Robert T. Dorr
- College of Medicine, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85724, USA
- AmpliMed Corporation, 4380 N. Campbell Avenue, Suite 205, Tucson, AZ 85718, USA
| | - Betty Samulitis
- College of Medicine, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85724, USA
| | - Terry H. Landowski
- College of Medicine, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85724, USA
| |
Collapse
|
9
|
Shestopalova A. The investigation of the association of caffeine and actinocin derivatives in aqueous solution: A molecular dynamics simulation. J Mol Liq 2006. [DOI: 10.1016/j.molliq.2006.03.045] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Shestopalova AV. Computer simulation of the association of caffeine and actinocin derivatives in aqueous solutions. Biophysics (Nagoya-shi) 2006. [DOI: 10.1134/s0006350906030018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
11
|
Veselkov AN, Evstigneev MP, Rozvadovskaia AO, Mukhina IV, Davies DB. [A structural and thermodynamic analysis of novatrone and flavin mononucleotide heteroassociation in aqueous solution by 1H NMR spectroscopy]. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2005; 31:503-10. [PMID: 16245693 DOI: 10.1007/s11171-005-0062-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
A heteroassociation of antitumor antibiotic novatrone (NOV) and flavin mononucleotide (FMN) in aqueous solution was studied by one- and two-dimentional 1H NMR spectroscopy (500 MHz) to elucidate the molecular mechanism of the possible combined action of the antibiotic and vitamin. The equilibrium reaction constants, induced proton chemical shifts, and the thermodynamic parameters (deltaH and deltaS) of the NOV and FMN heteroassociation were determined from the concentration and temperature dependences of proton chemical shifts of the aromatic molecules. The most favorable structure of the 1 : 1 NOV-FMN complex was determined by both the method of molecular mechanics (X-PLOR software) and the induced proton chemical shifts of the molecules. An analysis of the results suggests that the NOV-FMN intermolecular complexes are mainly stabilized by stacking interactions of their aromatic chromophores. An additional stabilization is possible due to intermolecular hydrogen bonds. It was concluded that the aromatic molecules of vitamins, in particular, FMN, can form energetically favorable heterocomplexes with aromatic antitumor antibiotics in aqueous solutions, which could result in a modulation of their medical and biological action.
Collapse
|
12
|
Structural and thermodynamic analysis of heteroassociation of daunomycin and flavin mononucleotide molecules in water by 1H NMR spectroscopy. J STRUCT CHEM+ 2005. [DOI: 10.1007/s10947-006-0010-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
13
|
Veselkov DA, Karawajew L, Veselkov AN, Davies * DB. 1H NMR investigation of the hetero-association of phenanthridine dyes with Daunomycin: effect of substitution of amino with azido groups in the dye chromophore. Mol Phys 2004. [DOI: 10.1080/00268970412331292731] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Waltmire CN, Alberts DS, Dorr RT. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer. Anticancer Drugs 2001; 12:595-602. [PMID: 11487716 DOI: 10.1097/00001813-200108000-00006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Combination chemotherapy for non-small cell lung cancer (NSCLC) and ovarian cancer typically consists of a regimen of a taxane such as paclitaxel and a platinum-containing agent. Bleomycin, which halts cell cycle progression at G2 phase, is an agent which might thereby increase taxane cytotoxicity. The goal of this study was to evaluate the effect of different paclitaxel-platinum or paclitaxel-bleomycin schedules on cytotoxicity in human NSCLC and ovarian cancer cells. The simultaneous combination of paclitaxel and carboplatin exhibited simple additivity in vitro, while sequential exposure studies indicated that carboplatin followed by paclitaxel produced greater than additive cytotoxicity using the isobologram analysis of combinatorial effects. In contrast, the simultaneous combination of paclitaxel and bleomycin consistently exhibited greater than additive effects indicating a potentially synergistic combination. Sequential exposure studies of bleomycin followed by paclitaxel produced similar synergistic findings. Experiments in SCID mice evaluating the combinations of paclitaxel and bleomycin supported the in vitro results, as significantly enhanced A549 lung tumor growth inhibition was observed when paclitaxel was administered 1 h after bleomycin. The synergistic activity shown by the combination of bleomycin and paclitaxel indicates a potentially beneficial novel combination for treatment of NSCLC and ovarian cancer.
Collapse
Affiliation(s)
- C N Waltmire
- Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
| | | | | |
Collapse
|
15
|
Veselkov AN, Evstigneev MP, Veselkov DA, Davies DB. A general nuclear magnetic resonance analysis of hetero-association of aromatic molecules in aqueous solution. J Chem Phys 2001. [DOI: 10.1063/1.1359767] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
DelaFlor-Weiss E, Uziely B, Muggia FM. Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums. Ann Oncol 1993; 4:723-33. [PMID: 8280652 DOI: 10.1093/oxfordjournals.annonc.a058656] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The feasibility to deliver chemotherapeutic agents by protracted i.v. infusion has greatly increased in the recent past. Indwelling ports, longer lasting central venous catheters requiring less than daily maintenance 'flushing', surgical expertise in placement, use in analgesia and nutrition, and 'smart' pump technology have all contributed to their increasing popularity. Justification for use of infusions in cancer chemotherapy has been slow in appearing with few studies proceeding to the comparative stage. This review will focus on three drugs in common use in cancer treatment, with the purpose of appraising the role of such infusions in cancer therapeutics and of deriving some lessons that might be applicable to other drugs or to drug development in general. For fluorouracil and doxorubicin the rationale and clinical findings favoring further development of infusion regimens is particularly strong. In the case of platinum compounds, some toxicologic advantages have emerged, but other measures designed to protect against the toxicities of cisplatin compete with infusion regimens in this regard. The therapeutic potential for this form of drug delivery, therefore, appears still confined to a subset of patients. Stronger rationales for the use of protracted infusions may be forthcoming from pharmacodynamic findings as in the case of etoposide, combined modality therapy with radiation for FU and cisplatin, biochemical modulation for FU, and reversal of multidrug resistance and its modulation for doxorubicin. While awaiting research into these areas of clinical and pre-clinical investigations, the role of infusion appears most evident in the cardiotoxicity protection of anthracyclines, and in further efficacy exploration (through dose or modulation) of FU. Both mechanistic and pharmacologic considerations could also provide additional stimulus for development of new formulations such as long circulating liposomes, and drugs more suitable for oral administration.
Collapse
Affiliation(s)
- E DelaFlor-Weiss
- Division of Medical Oncology, Norris Cancer Center, University of Southern California, Los Angeles
| | | | | |
Collapse
|